Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Reduces Pancytopenia After Rescue Therapy in a Patient with Hodgkin's Lymphoma

After several relapses, a stage IV lymphocyte depletion Hodgkin Lymphoma patient, with a bone marrow progenitor compartment depleted by several courses of chemotherapy, received further combination chemotherapy which caused severe and long-lasting pancytopenia. Because of an objective degree of tumor regression, a second identical course was administered, followed by Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in an attempt to accelerate bone marrow recovery. This led to a significantly shorter period of neutropenia and thrombocytopenia with no additional red blood cell and platelet transfusion requirements. Furthermore, the neutropenic phase was not accompanied by septic complications. It is suggested that patients with solid tumors, even with a severely compromised bone marrow after several chemotherapy courses, may benefit from GM-CSF administration after rescue chemotherapy.